Tech Company Financing Transactions
LENZ Therapeutics Funding Round
LENZ Therapeutics closed a $47 million Series A funding round on 6/23/2021. Investors included RA Capital and Versant Ventures.
Transaction Overview
Company Name
Announced On
6/23/2021
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series A
Investors
RA Capital (Zach Scheiner)
Versant Ventures (Clare Ozawa)
Proceeds Purpose
Proceeds from the financing will be utilized to progress the company's lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 S Hwy. 101
San Diego, CA 92075
USA
San Diego, CA 92075
USA
Phone
Undisclosed
Website
Email Address
Overview
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eef Schimmelpennink
Chief Medical Officer
Marc Odrich
Founder
Gerald Horn
VP - Bus. Development
Shawn Olsson
Browse more venture capital transactions:
Prev: 6/23/2021: MAJORITY venture capital transaction
Next: 6/23/2021: Facet Data venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs